LOGIN  |  REGISTER
Astria Therapeutics
Astria Therapeutics

Humana to Present at the Wells Fargo 2023 Healthcare Conference

August 22, 2023 | Last Trade: US$247.10 11.32 4.80

LOUISVILLE, Ky. / Aug 22, 2023 / Business Wire / Humana Inc. (NYSE: HUM) announced today that Bruce D. Broussard, President and Chief Executive Officer, and Susan M. Diamond, Chief Financial Officer, will make a presentation to investors at the Wells Fargo Healthcare Conference on Wednesday, September 6, 2023, at 8:00 a.m. Eastern time.

A live audio webcast of the presentation will be available via Humana’s Investor Relations page at humana.com. The company suggests webcast participants sign on approximately 15 minutes in advance of the presentation to allow time to run a system test and download any free software needed for access purposes.

About Humana

Humana Inc. is committed to putting health first – for our teammates, our customers, and our company. Through our Humana insurance services, and our CenterWell health care services, we make it easier for the millions of people we serve to achieve their best health – delivering the care and service they need, when they need it. These efforts are leading to a better quality of life for people with Medicare, Medicaid, families, individuals, military service personnel, and communities at large. Learn more about what we offer at Humana.com and at CenterWell.com.

Recursion

Stock Quote

Featured Stock

Amneal Pharmaceuticals

Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...

CLICK TO LEARN MORE

Featured Stock

Terns Pharmaceuticals

Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB